Top 10 Drug Delivery Technologies Market
Report Description:
STUDY GOALS AND OBJECTIVES
More than 25% of the marketed drugs fail to provide expected commercial returns due to drug distribution and absorption levels within the body (pharmacokinetics) therefore signifying the importance of drug delivery systems. Rapid enhancements in drug discovery technologies have lead to developments in proteomics and genomics and had a greater impact on drug delivery technology market. The changing market trends, with quick cycle of innovations have compelled market participants to clearly understand changing dynamics and focus on emerging technology and enhance market positions in terms of revenues, growth and geographical presence.
SCOPE AND FORMAT
The report intensively evaluates drug delivery technologies with respect to revenues, growth, therapeutic areas, patents registered and industry focus to arrive at top 10 drug delivery technologies. The key drug delivery technologies discussed in the report are:
INTENDED AUDIENCES
Each of the section will provide market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide market tables for various geographic regions covering sub segments and micro markets. In addition the report also provides 40 companies. Key market developments will be sourced from the top companies that are profiled. Secondary research will progress through both paid and unpaid sources. We will conduct primary research to provide in-depth understanding of the market.
STUDY GOALS AND OBJECTIVES
- To define and measure drug delivery market and its various sub-segments with respect to types of systems, by mode of drug delivery, by therapeutics and others.
- To identify major drivers and restraints of the market
- To evaluate comprehensively all drug delivery technologies and benchmark them against various parameters to identify top ten technologies.
- To identify and analyze comprehensively market structure with respect to the factors influencing market growth and industry specific challenges.
- To analyze trends and forecasts of drug delivery market and its segments
- To identify major stakeholders in the market and draw a competitive landscape for market leaders for each of the drug delivery technology market.
- To analyze opportunities in the market for stakeholders
- To strategically analyze micro markets with respect to their individual growth trends, future prospects and contribution to the total market
- To understand regulatory framework, design criteria, pricing issues, threat from alternative methods available in the market.
- To analyze and forecast revenues of market segments with respect to geographies (North America, Europe, Asia and Rest of the World
- To provide comprehensive analysis of top players in the drug delivery technology market.
- To effectively scope out and justify evaluation and provide sufficient basis of ranking top ten drug delivery technologies.
More than 25% of the marketed drugs fail to provide expected commercial returns due to drug distribution and absorption levels within the body (pharmacokinetics) therefore signifying the importance of drug delivery systems. Rapid enhancements in drug discovery technologies have lead to developments in proteomics and genomics and had a greater impact on drug delivery technology market. The changing market trends, with quick cycle of innovations have compelled market participants to clearly understand changing dynamics and focus on emerging technology and enhance market positions in terms of revenues, growth and geographical presence.
SCOPE AND FORMAT
The report intensively evaluates drug delivery technologies with respect to revenues, growth, therapeutic areas, patents registered and industry focus to arrive at top 10 drug delivery technologies. The key drug delivery technologies discussed in the report are:
- Oral drug delivery technologies
- Injectable drug delivery technologies
- Pulmonary drug delivery technologies
- Transdermal drug delivery technologies
- Other drug delivery technologies
INTENDED AUDIENCES
- Drug delivery technology – manufacturers, suppliers and dealers
- Pharmaceutical and biotech companies
- Healthcare providers
- Potential investors in the drug delivery technology market
Each of the section will provide market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide market tables for various geographic regions covering sub segments and micro markets. In addition the report also provides 40 companies. Key market developments will be sourced from the top companies that are profiled. Secondary research will progress through both paid and unpaid sources. We will conduct primary research to provide in-depth understanding of the market.
EXECUTIVE SUMMARY
OBJECTIVE
MARKET SCENARIO
EMERGING TECHNOLOGIES
1 INTRODUCTION
1.1 KEY TAKE-AWAYS
1.2 REPORT DESCRIPTION
1.3 MARKETS COVERED
1.4 STAKEHOLDERS
1.5 RESEARCH METHODOLOGY
2 SUMMARY
3 MARKET OVERVIEW
3.1 INTRODUCTION
3.2 ROLE OF DRUG DELIVERY IN DRUG LIFE CYCLE
3.3 STAKEHOLDERS
3.4 CHALLENGES
3.4.1 GOVERNMENT REGULATIONS
3.4.2 PRICING PRESSURE, REIMBURSEMENTS, & THIRD-PARTY DEPENDENCE
3.4.3 PATENT LITIGATIONS
3.4.4 PHARMA COMPANIES DEVELOP IN-HOUSE DRUG DELIVERY CAPABILITIES
3.5 CONVENIENCE IS THE KEY FOR COMMERCIAL SUCCESS OF FUTURE DRUGS
3.6 PATENT ANALYSIS
4 MARKET DYNAMICS
4.1 INTRODUCTION
4.2 DRIVERS
4.2.1 PATENT EXPIRATION OF DRUGS
4.2.2 NEED FOR EFFECTIVE DELIVERY OF NOVEL PHARMACEUTICALS & BIOPHARMACEUTICALS
4.2.3 REDUCE ATTRITION RATES & FASTER DRUG DISCOVERY/DEVELOPMENT PROCESSES
4.2.4 EXPANDED APPLICATIONS OF UNCONVENTIONAL MODES OF DRUG DELIVERY
4.2.5 INNOVATIONS IN DRUG DELIVERY TECHNOLOGIES
4.3 RESTRAINTS
4.3.1 DRUG FAILURES RAISE CONCERNS ON ROI
4.3.2 U.S. HEALTHCARE REFORMS
4.4 OPPORTUNITIES
4.4.1 HOME-CARE DRUG DELIVERY DEVICES & SELF-ADMINISTRATION
4.4.2 NICHE THERAPEUTIC AREAS
4.4.3 WELLNESS PRODUCTS
5 CONTROLLED RELEASE TECHNOLOGY
5.1 INTRODUCTION
5.1.1 KEY MARKET PLAYERS
5.2 DRIVERS
5.2.1 CONTROLLED RELEASE FORMULATIONS IN KEY THERAPEUTIC AREAS
5.2.2 ONCE-A-DAY FORMULATIONS
5.2.3 COST EFFECTIVE
5.3 RESTRAINTS
5.3.1 LIMITED NUMBER OF MATERIALS
5.3.2 TECHNICAL BARRIERS
5.4 OPPORTUNITIES
5.4.1 PARTICULATE & CHRONOPHARMACOKINETIC SYSTEMS
5.4.2 MUCOADHESIVE DRUG DELIVERY
5.5 BIODEGRADABLE POLYMERS
5.6 HYDROGEL
5.7 MULTIPARTICULATE BEAD SYSTEMS
5.8 ION EXCHANGE RESINS
5.9 OSMOTIC PRESSURE CONTROLLED SYSTEMS
5.10 DISSOLUTION/DIFFUSION SYSTEMS
5.10.1 MATRIX SYSTEMS
5.10.2 RESERVOIR SYSTEMS
5.11 OTHERS
5.12 REGULATORY ENVIRONMENT
5.13 CONTROLLED RELEASE VS IMMEDIATE RELEASE FORMULATIONS
5.14 INNOVATIONS IN CONTROLLED RELEASE TECHNOLOGIES
5.15 BURNING ISSUES
5.16 WINNING IMPERATIVES
5.17 COMPETITIVE DEVELOPMENTS
6 TARGETED DELIVERY
6.1 INTRODUCTION
6.1.1 KEY MARKET PLAYERS
6.2 DRIVERS & RESTRAINTS
6.2.1 INCREASED DEMAND FOR TREATMENT OF CANCEROUS TUMORS
6.2.2 LACK OF TARGETED DRUG DELIVERY TECHNOLOGIES FOR TREATMENT OF BRAIN TUMOR
6.2.3 HIGH COST OF TARGETED ANTIBODY-BASED CANCER THERAPEUTICS
6.3 OPPORTUNITY
6.3.1 NOVEL TARGETED DRUG DELIVERY SYSTEMS
6.4 TARGETING LIGANDS
6.4.1.1 Antibody fragment drug conjugate delivery
6.4.1.2 Antibody directed enzyme prodrug targeted delivery
6.4.1.3 Peptide-targeted delivery
6.4.1.4 Small molecule conjugate delivery
6.4.1.5 Others
6.5 NON-BIOLOGICAL TARGETING PLATFORMS
6.6 CURRENTLY MARKETED TARGETED THERAPIES
6.7 IMPACT OF TARGETED DRUG DELIVERY IN CANCER & OTHER CHRONIC CONDITIONS
6.8 INNOVATIONS
6.9 INDUSTRY INSIGHTS
6.10 WINNING IMPERATIVES
7 ENCAPSULATION TECHNOLOGIES
7.1 INTRODUCTION
7.1.1 KEY MARKET PLAYERS
7.2 DRIVERS & RESTRAINTS
7.2.1 ENHANCED BIOAVAILABILITY
7.2.2 EXTENSIVE USAGE IN TASTE MASKING & FASTER DISSOLVING PILLS
7.2.3 ECONOMICALLY FEASIBLE
7.2.4 RELUCTANCE IN INVESTING IN NOVEL TECHNOLOGIES
7.3 OPPORTUNITY
7.3.1 SOPHISTICATED MICROENCAPSULATION SYSTEMS
7.4 TASTE MASKING
7.5 FAST DISSOLVING PILLS
7.6 EVOLUTION OF ENCAPSULATION TECHNOLOGIES
7.7 APPLICATION OF ENCAPSULATION TECHNOLOGIES IN DIFFERENT MODES OF DRUG DELIVERY
7.8 INDUSTRY INSIGHTS
7.9 WINNING IMPERATIVES
7.10 COMPETITIVE DEVELOPMENTS
8 TOPICAL FORMULATIONS
8.1 INTRODUCTION
8.1.1 KEY MARKET PLAYERS
8.2 DRIVERS & RESTRAINTS
8.2.1 BURN & WOUND TREATMENT
8.2.2 BYPASSING FIRST PASS EFFECT
8.2.3 CONVENIENCE FACTOR
8.2.4 USAGE IN LIMITED THERAPEUTIC AREAS
8.3 OPPORTUNITY
8.3.1 TECHNOLOGY ADVANCEMENTS EXPAND APPLICATIONS
8.4 GEL TECHNOLOGY
8.5 MICROEMULSIONS
8.6 BIPHASIC SYSTEM
8.7 OTHERS
8.8 INDUSTRY INSIGHTS
8.9 WINNING IMPERATIVES
8.1 COMPETITIVE DEVELOPMENTS
9 INHALER TECHNOLOGY
9.1 INTRODUCTION
9.1.1 KEY MARKET PLAYERS
9.2 DRIVERS & RESTRAINTS
9.2.1 INCREASE IN ASTHMA & COPD PATIENTS
9.2.2 TECHNOLOGICAL ADVANCEMENTS IN AEROSOL FORMULATION AND DEVICE DESIGN
9.2.3 EASE OF USE, SELF-ADMINISTRATION, & PAINLESS DRUG DELIVERY
9.2.4 FAILURE OF EXUBERA
9.3 OPPORTUNITY
9.3.1 APPLICATION IN NON-RESPIRATORY CONDITIONS
9.4 DRY POWDER INHALERS
9.5 METERED DOSE INHALERS
9.6 NEBULIZERS
9.7 EVOLUTION OF INHALER DEVICES
9.8 REGULATORY ENVIRONMENT
9.9 TECHNOLOGY INNOVATIONS
9.10 INDUSTRY INSIGHTS
9.11 WINNING IMPERATIVES
9.12 COMPETITIVE DEVELOPMENTS
10 INJECTABLE DRUG DELIVERY
10.1 INJECTION DEVICES
10.1.1 KEY MARKET DYNAMICS
10.1.1.1 Drivers
10.1.1.1.1 Growth of self-administration therapies
10.1.1.1.2 Needle-stick legislation
10.1.1.1.3 Increasing acceptance by physicians and patients
10.1.1.1.4 Reducing cost of treatment
10.1.1.2 Restraints
10.1.1.2.1 Need of new drug formulation
10.1.1.3 Opportunities
10.1.1.3.1 Product differentiation through added functional features
10.1.1.3.2 Expansion to new areas
10.2 CRITERIA FOR SELECTION OF INJECTABLE DEVICE
10.3 KEY DEVELOPMENTS
10.3.1 DEVELOPMENT OF MICRONEEDLES
10.3.2 DEVELOPMENT OF NEEDLE-FREE DEVICES FOR ADMINISTRATION OF POWDERED DRUGS
10.4 CONVENTIONAL INJECTABLES
10.5 PREFILLED SYRINGES (PFS)
10.5.1 KEY MARKET DYNAMICS
10.5.1.1 Drivers
10.5.1.1.1 Growing market for self-injection devices
10.5.1.1.2 Wastage control and cost reduction through less overfill
10.5.1.1.3 Ease of manufacture & convenient usability
10.5.1.2 Restraints
10.5.1.2.1 Threat from needle-free devices
10.5.1.2.2 Protecting product quality
10.5.2 GLASS PFS
10.5.3 PLASTIC PFS
10.6 SELF INJECTION DEVICES
10.6.1 AUTO INJECTORS
10.6.1.1 Reusable auto-injectors
10.6.1.2 Disposable auto-injectors
10.6.2 PEN INJECTORS
10.6.2.1 Reusable pen injectors
10.6.2.2 Disposable pen injectors
10.6.3 NEEDLE-FREE INJECTORS (NFI)
10.6.3.1 Reusable NFIs
10.6.3.2 Disposable NFIs
10.7 OTHERS
11 TRANSDERMAL PATCH
11.1 INTRODUCTION
11.1.1 KEY MARKET PLAYERS
11.2 DRIVERS
11.2.1 REDUCED SIDE EFFECTS & BETTER EFFICACY
11.2.2 CONVENIENT & LESS PAINFUL
11.3 RESTRAINTS
11.3.1 RECALL OF DURAGESIC & NEGATIVE PUBLICITY OF ORTHO EVRA PATCH
11.3.2 LOW SKIN PERMEABILITY OF DRUGS
11.4 OPPORTUNITIES
11.4.1 NEW PRODUCTS
11.4.1.1 Contraceptive patch
11.4.1.2 Pain management patch
11.4.1.3 Estrogen/hormone replacement patch
11.5 INDUSTRY INSIGHTS
11.6 WINNING IMPERATIVES
11.7 COMPETITIVE DEVELOPMENTS
12 IMPLANTABLE DRUG DELIVERY
12.1 INTRODUCTION
12.2 DRIVERS & RESTRAINTS
12.2.1 SELECTIVE DRUG DELIVERY & LOW AMOUNT OF ACTIVE DRUG INGREDIENT
12.2.2 DOSING ADMINISTRATION NOT REQUIRED
12.2.3 INCONVENIENCE
12.3 OPPORTUNITY
12.3.1 TECHNOLOGICAL ADVANCES ENHANCE APPLICATIONS
12.4 CORONARY (DRUG ELUTING) STENTS
12.5 IMPLANTABLE INFUSION PUMPS
12.6 OCULAR IMPLANTS & OTHERS
12.7 INDUSTRY INSIGHTS
12.8 WINNING IMPERATIVES
13 LIPOSOMAL DRUG DELIVERY
13.1 INTRODUCTION
13.2 DRIVERS & RESTRAINTS
13.2.1 ENHANCED USAGE IN CANCER
13.2.2 EASY MANUFACTURING PROCEDURE & COST EFFECTIVENESS
13.2.3 SIDE EFFECTS
13.3 OPPORTUNITY
13.3.1 NANOSCALE LIPOSOME DRUG DELIVERY
13.4 INDUSTRY INSIGHTS
13.5 WINNING IMPERATIVES
13.6 COMPETITIVE DEVELOPMENTS
14 PEGYLATION TECHNOLOGIES
14.1 INTRODUCTION
14.2 DRIVERS & RESTRAINTS
14.2.1 BIOLOGICAL DRUGS
14.2.2 ENHANCED PHARMACOKINETIC PROPERTIES & REDUCED DOSAGE
14.2.3 EXPENSIVE MANUFACTURING PROCEDURE
14.3 OPPORTUNITY
14.3.1 TECHNOLOGICAL ADVANCES
14.4 INDUSTRY INSIGHTS
14.5 WINNING IMPERATIVES
15 COMPETITIVE LANDSCAPE
15.1 INTRODUCTION
15.2 ANALYSIS OF TOP PLAYERS
15.2.1 STRATEGY
15.2.2 INJECTABLE DRUG DELIVERY DEVICES MARKET SHARE
15.2.2.1 Top injectable drug delivery device companies & revenues, by segment
15.3 WINNING IMPERATIVES
15.3.1 ALLIANCES
15.3.2 POSITIONING OF DRUG DELIVERY TECHNOLOGY EARLY IN DRUG DISCOVERY
15.3.3 SHIFT FROM PURE DRUG DELIVERY TOWARD SPECIALTY PHARMACEUTICALS
15.4 STRATEGIC RECOMMENDATIONS
16 GEOGRAPHIC ANALYSIS
16.1 INTRODUCTION
16.2 NORTH AMERICA
16.3 EUROPE
16.4 ASIA
16.5 REST OF THE WORLD (ROW)
16.6 DECISION SUPPORT DATABASE
17 COMPANY PROFILES
17.1 3M COMPANY
17.1.1 OVERVIEW
17.1.2 FINANCIALS
17.1.3 PRODUCTS & SERVICES
17.1.4 STRATEGY
17.1.5 DEVELOPMENTS
17.2 ALKERMES, INC
17.2.1 OVERVIEW
17.2.2 FINANCIALS
17.2.3 PRODUCTS & SERVICES
17.2.4 STRATEGY
17.2.5 DEVELOPMENTS
17.3 ALTEA THERAPEUTICS INC.
17.3.1 OVERVIEW
17.3.2 PRODUCTS & SERVICES
17.3.3 STRATEGY
17.3.4 DEVELOPMENTS
17.4 ANTARES PHARMA INC.
17.4.1 OVERVIEW
17.4.2 FINANCIALS
17.4.3 PRODUCTS & SERVICES
17.4.4 STRATEGY
17.4.5 DEVELOPMENTS
17.5 A.P. PHARMA, INC.
17.5.1 OVERVIEW
17.5.2 FINANCIALS
17.5.3 PRODUCTS & SERVICES
17.5.4 STRATEGY
17.5.5 DEVELOPMENTS
17.6 APPLIED PHARMA
17.6.1 OVERVIEW
17.6.2 PRODUCTS & SERVICES
17.6.3 STRATEGY
17.6.4 DEVELOPMENTS
17.7 ARADIGM CORPORATION
17.7.1 OVERVIEW
17.7.2 FINANCIALS
17.7.3 PRODUCTS & SERVICES
17.7.4 STRATEGY
17.7.5 DEVELOPMENTS
17.8 BAXTER BIOPHARMA
17.8.1 OVERVIEW
17.8.2 PRODUCTS & SERVICES
17.8.3 FINANCIALS
17.8.4 STRATEGY
17.8.5 DEVELOP0MENTS
17.9 BECTON, DICKINSON AND COMPANY
17.9.1 OVERVIEW
17.9.2 PRODUCT & SERVICES
17.9.3 FINANCIALS
17.9.4 STRATEGY
17.9.5 DEVELOPMENTS
17.10 BIOJECT INC.
17.10.1 OVERVIEW
17.10.2 FINANCIALS
17.10.3 PRODUCTS & SERVICES
17.10.4 STRATEGY
17.10.5 DEVELOPMENTS
17.11 BIOVAIL CORPORATION (VALEANT PHARMACEUTICALS INTERNATIONAL INC.)
17.11.1 OVERVIEW
17.11.2 PRODUCTS & SERVICES
17.11.3 FINANCIALS
17.11.4 STRATEGY
17.11.5 DEVELOPMENTS
17.12 CIMA LABS INC.
17.12.1 OVERVIEW
17.12.2 PRODUCTS & SERVICES
17.12.3 STRATEGY
17.12.4 DEVELOPMENTS
17.13 ELAN CORPORATION PLC.
17.13.1 OVERVIEW
17.13.2 FINANCIALS
17.13.3 PRODUCTS & SERVICES
17.13.4 STRATEGY
17.13.5 DEVELOPMENTS
17.14 ENDO PHARMACEUTICALS
17.14.1 OVERVIEW
17.14.2 FINANCIALS
17.14.3 PRODUCTS & SERVICES
17.14.4 STRATEGY
17.14.5 DEVELOPMENTS
17.15 EURAND PHARMACEUTICALS
17.15.1 OVERVIEW
17.15.2 FINANCIALS
17.15.3 PRODUCTS & SERVICES
17.15.4 STRATEGY
17.15.5 DEVELOPMENTS
17.16 FLAMEL TECHNOLOGIES, INC
17.16.1 OVERVIEW
17.16.2 FINANCIALS
17.16.3 PRODUCTS & SERVICES
17.16.4 STRATEGY
17.16.5 DEVELOPMENTS
17.17 JOHNSON & JOHNSON LTD.
17.17.1 OVERVIEW
17.17.2 FINANCIALS
17.17.3 PRODUCTS & SERVICES
17.17.4 STRATEGY
17.17.5 DEVELOPMENTS
17.18 KV PHARMACEUTICAL
17.18.1 OVERVIEW
17.18.2 FINANCIALS
17.18.3 PRODUCTS & SERVICES
17.18.4 STRATEGY
17.18.5 DEVELOPMENTS
17.19 LABOPHARM INC.
17.19.1 OVERVIEW
17.19.2 FINANCIALS
17.19.3 PRODUCTS & SERVICES
17.19.4 STRATEGY
17.19.5 DEVELOPMENTS
17.20 NANOPASS TECHNOLOGIES LTD.
17.20.1 OVERVIEW
17.20.2 PRODUCTS & SERVICES
17.20.3 STRATEGY
17.20.4 DEVELOPMENTS
17.21 NEKTAR THERAPEUTICS
17.21.1 OVERVIEW
17.21.2 FINANCIALS
17.21.3 PRODUCTS & SERVICES
17.21.4 STRATEGY
17.21.5 DEVELOPMENTS
17.22 QLT INC.
17.22.1 OVERVIEW
17.22.2 FINANCIALS
17.22.3 PRODUCTS & SERVICES
17.22.4 STRATEGY
17.22.5 DEVELOPMENTS
17.23 SKYEPHARMA PLC.
17.23.1 OVERVIEW
17.23.2 FINANCIALS
17.23.3 PRODUCTS & SERVICES
17.23.4 STRATEGY
17.23.5 DEVELOPMENTS
17.24 SURMODICS, INC.
17.24.1 OVERVIEW
17.24.2 PRODUCTS & SERVICES
17.24.3 FINANCIALS
17.24.4 STRATEGY
17.24.5 DEVELOPMENTS
17.25 VECTURA GROUP PLC
17.25.1 OVERVIEW
17.25.2 FINANCIALS
17.25.3 PRODUCTS & SERVICES
17.25.4 STRATEGY
17.25.5 DEVELOPMENTS
17.26 YPSOMED HOLDING AG
17.26.1 OVERVIEW
17.26.2 FINANCIALS
17.26.3 PRODUCTS & SERVICES
17.26.4 STRATEGY
17.26.5 DEVELOPMENTS
17.27 ZOGENIX, INC.
17.27.1 OVERVIEW
17.27.2 PRODUCTS & SERVICES
17.27.3 STRATEGY
17.27.4 DEVELOP0MENTS
APPENDIX
U.S. PATENTS
EUROPE PATENTS
JAPAN PATENTS
OBJECTIVE
MARKET SCENARIO
EMERGING TECHNOLOGIES
1 INTRODUCTION
1.1 KEY TAKE-AWAYS
1.2 REPORT DESCRIPTION
1.3 MARKETS COVERED
1.4 STAKEHOLDERS
1.5 RESEARCH METHODOLOGY
2 SUMMARY
3 MARKET OVERVIEW
3.1 INTRODUCTION
3.2 ROLE OF DRUG DELIVERY IN DRUG LIFE CYCLE
3.3 STAKEHOLDERS
3.4 CHALLENGES
3.4.1 GOVERNMENT REGULATIONS
3.4.2 PRICING PRESSURE, REIMBURSEMENTS, & THIRD-PARTY DEPENDENCE
3.4.3 PATENT LITIGATIONS
3.4.4 PHARMA COMPANIES DEVELOP IN-HOUSE DRUG DELIVERY CAPABILITIES
3.5 CONVENIENCE IS THE KEY FOR COMMERCIAL SUCCESS OF FUTURE DRUGS
3.6 PATENT ANALYSIS
4 MARKET DYNAMICS
4.1 INTRODUCTION
4.2 DRIVERS
4.2.1 PATENT EXPIRATION OF DRUGS
4.2.2 NEED FOR EFFECTIVE DELIVERY OF NOVEL PHARMACEUTICALS & BIOPHARMACEUTICALS
4.2.3 REDUCE ATTRITION RATES & FASTER DRUG DISCOVERY/DEVELOPMENT PROCESSES
4.2.4 EXPANDED APPLICATIONS OF UNCONVENTIONAL MODES OF DRUG DELIVERY
4.2.5 INNOVATIONS IN DRUG DELIVERY TECHNOLOGIES
4.3 RESTRAINTS
4.3.1 DRUG FAILURES RAISE CONCERNS ON ROI
4.3.2 U.S. HEALTHCARE REFORMS
4.4 OPPORTUNITIES
4.4.1 HOME-CARE DRUG DELIVERY DEVICES & SELF-ADMINISTRATION
4.4.2 NICHE THERAPEUTIC AREAS
4.4.3 WELLNESS PRODUCTS
5 CONTROLLED RELEASE TECHNOLOGY
5.1 INTRODUCTION
5.1.1 KEY MARKET PLAYERS
5.2 DRIVERS
5.2.1 CONTROLLED RELEASE FORMULATIONS IN KEY THERAPEUTIC AREAS
5.2.2 ONCE-A-DAY FORMULATIONS
5.2.3 COST EFFECTIVE
5.3 RESTRAINTS
5.3.1 LIMITED NUMBER OF MATERIALS
5.3.2 TECHNICAL BARRIERS
5.4 OPPORTUNITIES
5.4.1 PARTICULATE & CHRONOPHARMACOKINETIC SYSTEMS
5.4.2 MUCOADHESIVE DRUG DELIVERY
5.5 BIODEGRADABLE POLYMERS
5.6 HYDROGEL
5.7 MULTIPARTICULATE BEAD SYSTEMS
5.8 ION EXCHANGE RESINS
5.9 OSMOTIC PRESSURE CONTROLLED SYSTEMS
5.10 DISSOLUTION/DIFFUSION SYSTEMS
5.10.1 MATRIX SYSTEMS
5.10.2 RESERVOIR SYSTEMS
5.11 OTHERS
5.12 REGULATORY ENVIRONMENT
5.13 CONTROLLED RELEASE VS IMMEDIATE RELEASE FORMULATIONS
5.14 INNOVATIONS IN CONTROLLED RELEASE TECHNOLOGIES
5.15 BURNING ISSUES
5.16 WINNING IMPERATIVES
5.17 COMPETITIVE DEVELOPMENTS
6 TARGETED DELIVERY
6.1 INTRODUCTION
6.1.1 KEY MARKET PLAYERS
6.2 DRIVERS & RESTRAINTS
6.2.1 INCREASED DEMAND FOR TREATMENT OF CANCEROUS TUMORS
6.2.2 LACK OF TARGETED DRUG DELIVERY TECHNOLOGIES FOR TREATMENT OF BRAIN TUMOR
6.2.3 HIGH COST OF TARGETED ANTIBODY-BASED CANCER THERAPEUTICS
6.3 OPPORTUNITY
6.3.1 NOVEL TARGETED DRUG DELIVERY SYSTEMS
6.4 TARGETING LIGANDS
6.4.1.1 Antibody fragment drug conjugate delivery
6.4.1.2 Antibody directed enzyme prodrug targeted delivery
6.4.1.3 Peptide-targeted delivery
6.4.1.4 Small molecule conjugate delivery
6.4.1.5 Others
6.5 NON-BIOLOGICAL TARGETING PLATFORMS
6.6 CURRENTLY MARKETED TARGETED THERAPIES
6.7 IMPACT OF TARGETED DRUG DELIVERY IN CANCER & OTHER CHRONIC CONDITIONS
6.8 INNOVATIONS
6.9 INDUSTRY INSIGHTS
6.10 WINNING IMPERATIVES
7 ENCAPSULATION TECHNOLOGIES
7.1 INTRODUCTION
7.1.1 KEY MARKET PLAYERS
7.2 DRIVERS & RESTRAINTS
7.2.1 ENHANCED BIOAVAILABILITY
7.2.2 EXTENSIVE USAGE IN TASTE MASKING & FASTER DISSOLVING PILLS
7.2.3 ECONOMICALLY FEASIBLE
7.2.4 RELUCTANCE IN INVESTING IN NOVEL TECHNOLOGIES
7.3 OPPORTUNITY
7.3.1 SOPHISTICATED MICROENCAPSULATION SYSTEMS
7.4 TASTE MASKING
7.5 FAST DISSOLVING PILLS
7.6 EVOLUTION OF ENCAPSULATION TECHNOLOGIES
7.7 APPLICATION OF ENCAPSULATION TECHNOLOGIES IN DIFFERENT MODES OF DRUG DELIVERY
7.8 INDUSTRY INSIGHTS
7.9 WINNING IMPERATIVES
7.10 COMPETITIVE DEVELOPMENTS
8 TOPICAL FORMULATIONS
8.1 INTRODUCTION
8.1.1 KEY MARKET PLAYERS
8.2 DRIVERS & RESTRAINTS
8.2.1 BURN & WOUND TREATMENT
8.2.2 BYPASSING FIRST PASS EFFECT
8.2.3 CONVENIENCE FACTOR
8.2.4 USAGE IN LIMITED THERAPEUTIC AREAS
8.3 OPPORTUNITY
8.3.1 TECHNOLOGY ADVANCEMENTS EXPAND APPLICATIONS
8.4 GEL TECHNOLOGY
8.5 MICROEMULSIONS
8.6 BIPHASIC SYSTEM
8.7 OTHERS
8.8 INDUSTRY INSIGHTS
8.9 WINNING IMPERATIVES
8.1 COMPETITIVE DEVELOPMENTS
9 INHALER TECHNOLOGY
9.1 INTRODUCTION
9.1.1 KEY MARKET PLAYERS
9.2 DRIVERS & RESTRAINTS
9.2.1 INCREASE IN ASTHMA & COPD PATIENTS
9.2.2 TECHNOLOGICAL ADVANCEMENTS IN AEROSOL FORMULATION AND DEVICE DESIGN
9.2.3 EASE OF USE, SELF-ADMINISTRATION, & PAINLESS DRUG DELIVERY
9.2.4 FAILURE OF EXUBERA
9.3 OPPORTUNITY
9.3.1 APPLICATION IN NON-RESPIRATORY CONDITIONS
9.4 DRY POWDER INHALERS
9.5 METERED DOSE INHALERS
9.6 NEBULIZERS
9.7 EVOLUTION OF INHALER DEVICES
9.8 REGULATORY ENVIRONMENT
9.9 TECHNOLOGY INNOVATIONS
9.10 INDUSTRY INSIGHTS
9.11 WINNING IMPERATIVES
9.12 COMPETITIVE DEVELOPMENTS
10 INJECTABLE DRUG DELIVERY
10.1 INJECTION DEVICES
10.1.1 KEY MARKET DYNAMICS
10.1.1.1 Drivers
10.1.1.1.1 Growth of self-administration therapies
10.1.1.1.2 Needle-stick legislation
10.1.1.1.3 Increasing acceptance by physicians and patients
10.1.1.1.4 Reducing cost of treatment
10.1.1.2 Restraints
10.1.1.2.1 Need of new drug formulation
10.1.1.3 Opportunities
10.1.1.3.1 Product differentiation through added functional features
10.1.1.3.2 Expansion to new areas
10.2 CRITERIA FOR SELECTION OF INJECTABLE DEVICE
10.3 KEY DEVELOPMENTS
10.3.1 DEVELOPMENT OF MICRONEEDLES
10.3.2 DEVELOPMENT OF NEEDLE-FREE DEVICES FOR ADMINISTRATION OF POWDERED DRUGS
10.4 CONVENTIONAL INJECTABLES
10.5 PREFILLED SYRINGES (PFS)
10.5.1 KEY MARKET DYNAMICS
10.5.1.1 Drivers
10.5.1.1.1 Growing market for self-injection devices
10.5.1.1.2 Wastage control and cost reduction through less overfill
10.5.1.1.3 Ease of manufacture & convenient usability
10.5.1.2 Restraints
10.5.1.2.1 Threat from needle-free devices
10.5.1.2.2 Protecting product quality
10.5.2 GLASS PFS
10.5.3 PLASTIC PFS
10.6 SELF INJECTION DEVICES
10.6.1 AUTO INJECTORS
10.6.1.1 Reusable auto-injectors
10.6.1.2 Disposable auto-injectors
10.6.2 PEN INJECTORS
10.6.2.1 Reusable pen injectors
10.6.2.2 Disposable pen injectors
10.6.3 NEEDLE-FREE INJECTORS (NFI)
10.6.3.1 Reusable NFIs
10.6.3.2 Disposable NFIs
10.7 OTHERS
11 TRANSDERMAL PATCH
11.1 INTRODUCTION
11.1.1 KEY MARKET PLAYERS
11.2 DRIVERS
11.2.1 REDUCED SIDE EFFECTS & BETTER EFFICACY
11.2.2 CONVENIENT & LESS PAINFUL
11.3 RESTRAINTS
11.3.1 RECALL OF DURAGESIC & NEGATIVE PUBLICITY OF ORTHO EVRA PATCH
11.3.2 LOW SKIN PERMEABILITY OF DRUGS
11.4 OPPORTUNITIES
11.4.1 NEW PRODUCTS
11.4.1.1 Contraceptive patch
11.4.1.2 Pain management patch
11.4.1.3 Estrogen/hormone replacement patch
11.5 INDUSTRY INSIGHTS
11.6 WINNING IMPERATIVES
11.7 COMPETITIVE DEVELOPMENTS
12 IMPLANTABLE DRUG DELIVERY
12.1 INTRODUCTION
12.2 DRIVERS & RESTRAINTS
12.2.1 SELECTIVE DRUG DELIVERY & LOW AMOUNT OF ACTIVE DRUG INGREDIENT
12.2.2 DOSING ADMINISTRATION NOT REQUIRED
12.2.3 INCONVENIENCE
12.3 OPPORTUNITY
12.3.1 TECHNOLOGICAL ADVANCES ENHANCE APPLICATIONS
12.4 CORONARY (DRUG ELUTING) STENTS
12.5 IMPLANTABLE INFUSION PUMPS
12.6 OCULAR IMPLANTS & OTHERS
12.7 INDUSTRY INSIGHTS
12.8 WINNING IMPERATIVES
13 LIPOSOMAL DRUG DELIVERY
13.1 INTRODUCTION
13.2 DRIVERS & RESTRAINTS
13.2.1 ENHANCED USAGE IN CANCER
13.2.2 EASY MANUFACTURING PROCEDURE & COST EFFECTIVENESS
13.2.3 SIDE EFFECTS
13.3 OPPORTUNITY
13.3.1 NANOSCALE LIPOSOME DRUG DELIVERY
13.4 INDUSTRY INSIGHTS
13.5 WINNING IMPERATIVES
13.6 COMPETITIVE DEVELOPMENTS
14 PEGYLATION TECHNOLOGIES
14.1 INTRODUCTION
14.2 DRIVERS & RESTRAINTS
14.2.1 BIOLOGICAL DRUGS
14.2.2 ENHANCED PHARMACOKINETIC PROPERTIES & REDUCED DOSAGE
14.2.3 EXPENSIVE MANUFACTURING PROCEDURE
14.3 OPPORTUNITY
14.3.1 TECHNOLOGICAL ADVANCES
14.4 INDUSTRY INSIGHTS
14.5 WINNING IMPERATIVES
15 COMPETITIVE LANDSCAPE
15.1 INTRODUCTION
15.2 ANALYSIS OF TOP PLAYERS
15.2.1 STRATEGY
15.2.2 INJECTABLE DRUG DELIVERY DEVICES MARKET SHARE
15.2.2.1 Top injectable drug delivery device companies & revenues, by segment
15.3 WINNING IMPERATIVES
15.3.1 ALLIANCES
15.3.2 POSITIONING OF DRUG DELIVERY TECHNOLOGY EARLY IN DRUG DISCOVERY
15.3.3 SHIFT FROM PURE DRUG DELIVERY TOWARD SPECIALTY PHARMACEUTICALS
15.4 STRATEGIC RECOMMENDATIONS
16 GEOGRAPHIC ANALYSIS
16.1 INTRODUCTION
16.2 NORTH AMERICA
16.3 EUROPE
16.4 ASIA
16.5 REST OF THE WORLD (ROW)
16.6 DECISION SUPPORT DATABASE
17 COMPANY PROFILES
17.1 3M COMPANY
17.1.1 OVERVIEW
17.1.2 FINANCIALS
17.1.3 PRODUCTS & SERVICES
17.1.4 STRATEGY
17.1.5 DEVELOPMENTS
17.2 ALKERMES, INC
17.2.1 OVERVIEW
17.2.2 FINANCIALS
17.2.3 PRODUCTS & SERVICES
17.2.4 STRATEGY
17.2.5 DEVELOPMENTS
17.3 ALTEA THERAPEUTICS INC.
17.3.1 OVERVIEW
17.3.2 PRODUCTS & SERVICES
17.3.3 STRATEGY
17.3.4 DEVELOPMENTS
17.4 ANTARES PHARMA INC.
17.4.1 OVERVIEW
17.4.2 FINANCIALS
17.4.3 PRODUCTS & SERVICES
17.4.4 STRATEGY
17.4.5 DEVELOPMENTS
17.5 A.P. PHARMA, INC.
17.5.1 OVERVIEW
17.5.2 FINANCIALS
17.5.3 PRODUCTS & SERVICES
17.5.4 STRATEGY
17.5.5 DEVELOPMENTS
17.6 APPLIED PHARMA
17.6.1 OVERVIEW
17.6.2 PRODUCTS & SERVICES
17.6.3 STRATEGY
17.6.4 DEVELOPMENTS
17.7 ARADIGM CORPORATION
17.7.1 OVERVIEW
17.7.2 FINANCIALS
17.7.3 PRODUCTS & SERVICES
17.7.4 STRATEGY
17.7.5 DEVELOPMENTS
17.8 BAXTER BIOPHARMA
17.8.1 OVERVIEW
17.8.2 PRODUCTS & SERVICES
17.8.3 FINANCIALS
17.8.4 STRATEGY
17.8.5 DEVELOP0MENTS
17.9 BECTON, DICKINSON AND COMPANY
17.9.1 OVERVIEW
17.9.2 PRODUCT & SERVICES
17.9.3 FINANCIALS
17.9.4 STRATEGY
17.9.5 DEVELOPMENTS
17.10 BIOJECT INC.
17.10.1 OVERVIEW
17.10.2 FINANCIALS
17.10.3 PRODUCTS & SERVICES
17.10.4 STRATEGY
17.10.5 DEVELOPMENTS
17.11 BIOVAIL CORPORATION (VALEANT PHARMACEUTICALS INTERNATIONAL INC.)
17.11.1 OVERVIEW
17.11.2 PRODUCTS & SERVICES
17.11.3 FINANCIALS
17.11.4 STRATEGY
17.11.5 DEVELOPMENTS
17.12 CIMA LABS INC.
17.12.1 OVERVIEW
17.12.2 PRODUCTS & SERVICES
17.12.3 STRATEGY
17.12.4 DEVELOPMENTS
17.13 ELAN CORPORATION PLC.
17.13.1 OVERVIEW
17.13.2 FINANCIALS
17.13.3 PRODUCTS & SERVICES
17.13.4 STRATEGY
17.13.5 DEVELOPMENTS
17.14 ENDO PHARMACEUTICALS
17.14.1 OVERVIEW
17.14.2 FINANCIALS
17.14.3 PRODUCTS & SERVICES
17.14.4 STRATEGY
17.14.5 DEVELOPMENTS
17.15 EURAND PHARMACEUTICALS
17.15.1 OVERVIEW
17.15.2 FINANCIALS
17.15.3 PRODUCTS & SERVICES
17.15.4 STRATEGY
17.15.5 DEVELOPMENTS
17.16 FLAMEL TECHNOLOGIES, INC
17.16.1 OVERVIEW
17.16.2 FINANCIALS
17.16.3 PRODUCTS & SERVICES
17.16.4 STRATEGY
17.16.5 DEVELOPMENTS
17.17 JOHNSON & JOHNSON LTD.
17.17.1 OVERVIEW
17.17.2 FINANCIALS
17.17.3 PRODUCTS & SERVICES
17.17.4 STRATEGY
17.17.5 DEVELOPMENTS
17.18 KV PHARMACEUTICAL
17.18.1 OVERVIEW
17.18.2 FINANCIALS
17.18.3 PRODUCTS & SERVICES
17.18.4 STRATEGY
17.18.5 DEVELOPMENTS
17.19 LABOPHARM INC.
17.19.1 OVERVIEW
17.19.2 FINANCIALS
17.19.3 PRODUCTS & SERVICES
17.19.4 STRATEGY
17.19.5 DEVELOPMENTS
17.20 NANOPASS TECHNOLOGIES LTD.
17.20.1 OVERVIEW
17.20.2 PRODUCTS & SERVICES
17.20.3 STRATEGY
17.20.4 DEVELOPMENTS
17.21 NEKTAR THERAPEUTICS
17.21.1 OVERVIEW
17.21.2 FINANCIALS
17.21.3 PRODUCTS & SERVICES
17.21.4 STRATEGY
17.21.5 DEVELOPMENTS
17.22 QLT INC.
17.22.1 OVERVIEW
17.22.2 FINANCIALS
17.22.3 PRODUCTS & SERVICES
17.22.4 STRATEGY
17.22.5 DEVELOPMENTS
17.23 SKYEPHARMA PLC.
17.23.1 OVERVIEW
17.23.2 FINANCIALS
17.23.3 PRODUCTS & SERVICES
17.23.4 STRATEGY
17.23.5 DEVELOPMENTS
17.24 SURMODICS, INC.
17.24.1 OVERVIEW
17.24.2 PRODUCTS & SERVICES
17.24.3 FINANCIALS
17.24.4 STRATEGY
17.24.5 DEVELOPMENTS
17.25 VECTURA GROUP PLC
17.25.1 OVERVIEW
17.25.2 FINANCIALS
17.25.3 PRODUCTS & SERVICES
17.25.4 STRATEGY
17.25.5 DEVELOPMENTS
17.26 YPSOMED HOLDING AG
17.26.1 OVERVIEW
17.26.2 FINANCIALS
17.26.3 PRODUCTS & SERVICES
17.26.4 STRATEGY
17.26.5 DEVELOPMENTS
17.27 ZOGENIX, INC.
17.27.1 OVERVIEW
17.27.2 PRODUCTS & SERVICES
17.27.3 STRATEGY
17.27.4 DEVELOP0MENTS
APPENDIX
U.S. PATENTS
EUROPE PATENTS
JAPAN PATENTS
LIST OF TABLES
1 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENTS 2008 – 2015 ($MILLION)
2 DRUGS SET FOR PATENT EXPIRATION (2010 – 2012)
3 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
4 GLOBAL CONTROLLED RELEASE TECHNOLOGY MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)
5 GLOBAL CONTROLLED RELEASE TECHNOLOGY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
6 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
7 GLOBAL BIODEGRADABLE POLYMERS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
8 GLOBAL HYDROGEL MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
9 GLOBAL MULTIPARTICULATE BEAD SYSTEMS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
10 GLOBAL ION EXCHANGE RESINS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
11 GLOBAL OSMOTIC PRESSURE CONTROLLED SYSTEMS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
12 GLOBAL DISSOLUTION/DIFFUSION SYSTEMS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
13 GLOBAL MATRIX SYSTEMS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
14 GLOBAL RESERVOIR SYSTEMS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
15 GLOBAL OTHER CONTROLLED RELEASE SYSTEMS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
16 GLOBAL TARGETED DELIVERY TECHNOLOGY MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)
17 GLOBAL TARGETED DELIVERY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
18 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
19 GLOBAL TARGETING LIGANDS MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)
20 GLOBAL TARGETING LIGANDS MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)
21 GLOBAL ANTIBODY FRAGMENT CONJUGATE DELIVERY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
22 GLOBAL ANTIBODY ENZYME DIRECTED PRODRUG DELIVERY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
23 GLOBAL PEPTIDE TARGETED DRUG DELIVERY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
24 GLOBAL SMALL MOLECULE CONJUGATE DELIVERY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
25 GLOBAL OTHER TARGETING LIGANDS BASED DELIVERY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
26 GLOBAL NON-BIOLOGICAL TARGETING PLATFORMS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
27 GLOBAL ENCAPSULATION TECHNOLOGY MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)
28 GLOBAL ENCAPSULATION TECHNOLOGIES MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
29 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
30 GLOBAL ENCAPSULATION MARKET IN TASTE MASKING, BY GEOGRAPHY 2008 – 2015 ($MILLION)
31 GLOBAL ENCAPSULATION MARKET IN FAST DISSOLVING, BY GEOGRAPHY 2008 – 2015 ($MILLION)
32 GLOBAL TOPICAL FORMULATIONS MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)
33 GLOBAL TOPICAL FORMULATIONS MARKET, BY GEOGRAPHY (2008 – 2015)
34 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
35 GLOBAL GEL TECHNOLOGY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
36 GLOBAL MICROEMULSIONS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
37 GLOBAL BIPHASIC SYSTEMS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
38 GLOBAL OTHER TOPICAL FORMULATIONS MARKET, BY GEOGRAPHY 2008 – 2015 ($ MILLION)
39 GLOBAL INHALER TECHNOLOGY MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)
40 GLOBAL INHALER TECHNOLOGY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
41 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
42 GLOBAL DRY POWDER INHALERS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
43 GLOBAL METERED DOSE INHALERS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
44 GLOBAL NEBULIZERS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
45 GLOBAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)
46 GLOBAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY GEOGRAPHY 2008-2015 ($MILLION)
47 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
48 GLOBAL CONVENTIONAL INJECTION DEVICES MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
49 GLOBAL PREFILLED SYRINGES MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)
50 GLOBAL PREFILLED SYRINGES MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
51 GLOBAL SELF-INJECTION DEVICES MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)
52 GLOBAL SELF-INJECTION DEVICES MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
53 GLOBAL AUTO INJECTOR MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)
54 GLOBAL AUTO INJECTOR MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
55 GLOBAL PEN INJECTOR MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)
56 GLOBAL PEN INJECTOR MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
57 MAJOR PRODUCTS IN THE NEEDLE FREE TECHNOLOGY
58 GLOBAL NEEDLE-FREE INJECTOR MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)
59 GLOBAL TRANSDERMAL PATCH TECHNOLOGY, BY GEOGRAPHY 2008 – 2015 ($MILLION)
60 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
61 GLOBAL IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY PRODUCTS (2008 – 2015)
62 GLOBAL IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
63 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
64 GLOBAL CORONARY STENTS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
65 GLOBAL IMPLANTABLE INFUSION PUMPS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
66 GLOBAL OCULAR IMPLANTS & OTHERS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
67 GLOBAL LIPOSOMAL DRUG DELIVERY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
68 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
69 GLOBAL PEGYLATION TECHNOLOGY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
70 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
71 REVENUE ANALYSIS (2008 – 2009)
72 ELAN TOTAL REVENUES BY DRUG (2008 – 2010)
73 ALKERMES TOTAL REVENUES, BY DRUG (2008 – 2010)
74 R&D EXPENDITURE (2008 – 2009)
75 ELAN’S PIPELINE DRUGS
76 BIOVAIL’S PIPELINE DRUGS
77 ALKERMES’S PIPELINE DRUGS
78 NEKTAR’S PIPELINE DRUGS
79 SKYE PHARMA’S PIPELINE DRUGS
80 TOP COMPANIES & THEIR STRATEGIES
81 BECTON DICKINSON – TOTAL REVENUES, BY SEGMENT ($MILLION)
82 BAXTER BIOPHARMA REVENUES, BY SEGMENT
83 YPSOMED - TOTAL REVENUES, BY SEGMENT ($MILLION)
84 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET, BY REGION (2008 – 2015)
85 NORTH AMERICAN TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENT
86 EUROPEAN TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENT
87 ASIAN TOP 10 DRUG DELIVERY TECHNOLOGIES
88 REST OF THE WORLD TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET
89 MULTIPLE SCLEROSIS PREVALENCE, BY GEOGRAPHY (2009)
90 OSTEOPOROSIS PREVALENCE, BY GEOGRAPHY (2009)
91 DIABETES PREVALENCE, BY GEOGRAPHY (2009)
92 CANCER PREVALENCE, BY GEOGRAPHY (2009)
93 RHEUMATOID ARTHRITIS PREVALENCE, BY GEOGRAPHY (2009)
94 ANEMIA PREVALENCE, BY GEOGRAPHY (2009)
95 HEPATITIS-C PREVALENCE, BY GEOGRAPHY (2009)
96 CROHN’S DISEASE PREVALENCE, BY GEOGRAPHY (2009)
97 PSORIASIS PREVALENCE, BY GEOGRAPHY (2009)
98 TOTAL REVENUES & R&D EXPENDITURE
99 TOTAL REVENUES, BY GEOGRAPHY
100 TOTAL REVENUES (2006 – 2010)
101 SEGMENT SPECIFIC REVENUES ($MILLION)
102 TOTAL REVENUES & R&D EXPENDITURE ($MILLION)
103 TOTAL REVENUES, BY GEOGRAPHY
104 REVENUES, BY SEGMENTS
105 TOTAL REVENUES & NET INCOME ($MILLION)
106 TOTAL REVENUES (2007 – 2009)
107 BAXTER BIOPHARMA – TOTAL REVENUES & R&D EXPENSES ($MILLION)
108 BAXTER BIOPHARMA – TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
109 BAXTER BIOPHARMA – TOTAL REVENUES, BY SEGMENTS ($MILLION)
110 BAXTER BIOPHARMA – TOTAL REVENUES FOR MEDICATION DELIVERY, BY SEGMENTS ($MILLION)
111 BECTON DICKINSON – TOTAL REVENUES & R&D EXPENDITURE ($MILLION)
112 BECTON DICKINSON – TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
113 BECTON DICKINSON – TOTAL REVENUES, BY SEGMENTS ($MILLION)
114 BECTON DICKINSON – TOTAL REVENUES FOR MEDICAL SURGICAL SYSTEMS, BY SEGMENTS ($MILLION)
115 TOTAL REVENUES & R&D EXPENDITURE
116 REVENUES, BY SEGMENTS ($MILLION)
117 TOTAL REVENUES & R&D EXPENDITURE ($MILLION)
118 U.S REVENUES OF BIOVAIL, BY PRODUCTS ($MILLION)
119 TOTAL PRODUCT REVENUES OF BIOVAIL PHARMACEUTICALS CANADA
120 TOTAL REVENUES & R&D EXPENDITURE
121 REVENUES, BY PRODUCTS
122 TOTAL REVENUES & R&D EXPENDITURE
123 TOTAL REVENUES & R&D EXPENDITURE ($MILLION)
124 PRODUCT SALES, BY THERAPEUTIC AREA
125 REVENUES & R&D EXPENDITURE
126 TOTAL REVENUES & R&D EXPENDITURE
127 REVENUES, BY BUSINESS SEGMENTS
128 REVENUES, BY PRODUCTS
129 REVENUES, BY GEOGRAPHY ($MILLION)
130 TOTAL REVENUES & EXPENDITURE
131 TOTAL REVENUES & R&D EXPENDITURE
132 NEKTAR – TOTAL REVENUES & R&D EXPENSES
133 NEKTAR – TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
134 QLT – TOTAL REVENUES & R&D EXPENSES ($MILLION)
135 QLT – TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
136 TOTAL REVENUES & R&D EXPENSES ($MILLION)
137 SURMODICS INC. – TOTAL REVENUES & R&D EXPENSES ($MILLION)
138 SURMODICS INC. – TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
139 SURMODICS INC. – TOTAL REVENUES, BY SEGMENTS ($MILLION)
140 TOTAL REVENUES & R&D EXPENDITURE
141 YPSOMED - TOTAL REVENUES & R&D EXPENSES ($MILLION)
142 YPSOMED - TOTAL REVENUES, BY SEGMENTS ($MILLION)
1 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENTS 2008 – 2015 ($MILLION)
2 DRUGS SET FOR PATENT EXPIRATION (2010 – 2012)
3 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
4 GLOBAL CONTROLLED RELEASE TECHNOLOGY MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)
5 GLOBAL CONTROLLED RELEASE TECHNOLOGY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
6 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
7 GLOBAL BIODEGRADABLE POLYMERS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
8 GLOBAL HYDROGEL MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
9 GLOBAL MULTIPARTICULATE BEAD SYSTEMS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
10 GLOBAL ION EXCHANGE RESINS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
11 GLOBAL OSMOTIC PRESSURE CONTROLLED SYSTEMS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
12 GLOBAL DISSOLUTION/DIFFUSION SYSTEMS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
13 GLOBAL MATRIX SYSTEMS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
14 GLOBAL RESERVOIR SYSTEMS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
15 GLOBAL OTHER CONTROLLED RELEASE SYSTEMS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
16 GLOBAL TARGETED DELIVERY TECHNOLOGY MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)
17 GLOBAL TARGETED DELIVERY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
18 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
19 GLOBAL TARGETING LIGANDS MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)
20 GLOBAL TARGETING LIGANDS MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)
21 GLOBAL ANTIBODY FRAGMENT CONJUGATE DELIVERY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
22 GLOBAL ANTIBODY ENZYME DIRECTED PRODRUG DELIVERY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
23 GLOBAL PEPTIDE TARGETED DRUG DELIVERY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
24 GLOBAL SMALL MOLECULE CONJUGATE DELIVERY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
25 GLOBAL OTHER TARGETING LIGANDS BASED DELIVERY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
26 GLOBAL NON-BIOLOGICAL TARGETING PLATFORMS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
27 GLOBAL ENCAPSULATION TECHNOLOGY MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)
28 GLOBAL ENCAPSULATION TECHNOLOGIES MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
29 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
30 GLOBAL ENCAPSULATION MARKET IN TASTE MASKING, BY GEOGRAPHY 2008 – 2015 ($MILLION)
31 GLOBAL ENCAPSULATION MARKET IN FAST DISSOLVING, BY GEOGRAPHY 2008 – 2015 ($MILLION)
32 GLOBAL TOPICAL FORMULATIONS MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)
33 GLOBAL TOPICAL FORMULATIONS MARKET, BY GEOGRAPHY (2008 – 2015)
34 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
35 GLOBAL GEL TECHNOLOGY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
36 GLOBAL MICROEMULSIONS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
37 GLOBAL BIPHASIC SYSTEMS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
38 GLOBAL OTHER TOPICAL FORMULATIONS MARKET, BY GEOGRAPHY 2008 – 2015 ($ MILLION)
39 GLOBAL INHALER TECHNOLOGY MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)
40 GLOBAL INHALER TECHNOLOGY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
41 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
42 GLOBAL DRY POWDER INHALERS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
43 GLOBAL METERED DOSE INHALERS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
44 GLOBAL NEBULIZERS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
45 GLOBAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)
46 GLOBAL INJECTABLE DRUG DELIVERY DEVICES MARKET, BY GEOGRAPHY 2008-2015 ($MILLION)
47 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
48 GLOBAL CONVENTIONAL INJECTION DEVICES MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
49 GLOBAL PREFILLED SYRINGES MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)
50 GLOBAL PREFILLED SYRINGES MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
51 GLOBAL SELF-INJECTION DEVICES MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)
52 GLOBAL SELF-INJECTION DEVICES MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
53 GLOBAL AUTO INJECTOR MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)
54 GLOBAL AUTO INJECTOR MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
55 GLOBAL PEN INJECTOR MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)
56 GLOBAL PEN INJECTOR MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
57 MAJOR PRODUCTS IN THE NEEDLE FREE TECHNOLOGY
58 GLOBAL NEEDLE-FREE INJECTOR MARKET, BY PRODUCTS 2008 – 2015 ($MILLION)
59 GLOBAL TRANSDERMAL PATCH TECHNOLOGY, BY GEOGRAPHY 2008 – 2015 ($MILLION)
60 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
61 GLOBAL IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY PRODUCTS (2008 – 2015)
62 GLOBAL IMPLANTABLE DRUG DELIVERY TECHNOLOGY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
63 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
64 GLOBAL CORONARY STENTS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
65 GLOBAL IMPLANTABLE INFUSION PUMPS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
66 GLOBAL OCULAR IMPLANTS & OTHERS MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
67 GLOBAL LIPOSOMAL DRUG DELIVERY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
68 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
69 GLOBAL PEGYLATION TECHNOLOGY MARKET, BY GEOGRAPHY 2008 – 2015 ($MILLION)
70 IMPACT ANALYSIS OF KEY MARKET DYNAMICS
71 REVENUE ANALYSIS (2008 – 2009)
72 ELAN TOTAL REVENUES BY DRUG (2008 – 2010)
73 ALKERMES TOTAL REVENUES, BY DRUG (2008 – 2010)
74 R&D EXPENDITURE (2008 – 2009)
75 ELAN’S PIPELINE DRUGS
76 BIOVAIL’S PIPELINE DRUGS
77 ALKERMES’S PIPELINE DRUGS
78 NEKTAR’S PIPELINE DRUGS
79 SKYE PHARMA’S PIPELINE DRUGS
80 TOP COMPANIES & THEIR STRATEGIES
81 BECTON DICKINSON – TOTAL REVENUES, BY SEGMENT ($MILLION)
82 BAXTER BIOPHARMA REVENUES, BY SEGMENT
83 YPSOMED - TOTAL REVENUES, BY SEGMENT ($MILLION)
84 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET, BY REGION (2008 – 2015)
85 NORTH AMERICAN TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENT
86 EUROPEAN TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET, BY SEGMENT
87 ASIAN TOP 10 DRUG DELIVERY TECHNOLOGIES
88 REST OF THE WORLD TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET
89 MULTIPLE SCLEROSIS PREVALENCE, BY GEOGRAPHY (2009)
90 OSTEOPOROSIS PREVALENCE, BY GEOGRAPHY (2009)
91 DIABETES PREVALENCE, BY GEOGRAPHY (2009)
92 CANCER PREVALENCE, BY GEOGRAPHY (2009)
93 RHEUMATOID ARTHRITIS PREVALENCE, BY GEOGRAPHY (2009)
94 ANEMIA PREVALENCE, BY GEOGRAPHY (2009)
95 HEPATITIS-C PREVALENCE, BY GEOGRAPHY (2009)
96 CROHN’S DISEASE PREVALENCE, BY GEOGRAPHY (2009)
97 PSORIASIS PREVALENCE, BY GEOGRAPHY (2009)
98 TOTAL REVENUES & R&D EXPENDITURE
99 TOTAL REVENUES, BY GEOGRAPHY
100 TOTAL REVENUES (2006 – 2010)
101 SEGMENT SPECIFIC REVENUES ($MILLION)
102 TOTAL REVENUES & R&D EXPENDITURE ($MILLION)
103 TOTAL REVENUES, BY GEOGRAPHY
104 REVENUES, BY SEGMENTS
105 TOTAL REVENUES & NET INCOME ($MILLION)
106 TOTAL REVENUES (2007 – 2009)
107 BAXTER BIOPHARMA – TOTAL REVENUES & R&D EXPENSES ($MILLION)
108 BAXTER BIOPHARMA – TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
109 BAXTER BIOPHARMA – TOTAL REVENUES, BY SEGMENTS ($MILLION)
110 BAXTER BIOPHARMA – TOTAL REVENUES FOR MEDICATION DELIVERY, BY SEGMENTS ($MILLION)
111 BECTON DICKINSON – TOTAL REVENUES & R&D EXPENDITURE ($MILLION)
112 BECTON DICKINSON – TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
113 BECTON DICKINSON – TOTAL REVENUES, BY SEGMENTS ($MILLION)
114 BECTON DICKINSON – TOTAL REVENUES FOR MEDICAL SURGICAL SYSTEMS, BY SEGMENTS ($MILLION)
115 TOTAL REVENUES & R&D EXPENDITURE
116 REVENUES, BY SEGMENTS ($MILLION)
117 TOTAL REVENUES & R&D EXPENDITURE ($MILLION)
118 U.S REVENUES OF BIOVAIL, BY PRODUCTS ($MILLION)
119 TOTAL PRODUCT REVENUES OF BIOVAIL PHARMACEUTICALS CANADA
120 TOTAL REVENUES & R&D EXPENDITURE
121 REVENUES, BY PRODUCTS
122 TOTAL REVENUES & R&D EXPENDITURE
123 TOTAL REVENUES & R&D EXPENDITURE ($MILLION)
124 PRODUCT SALES, BY THERAPEUTIC AREA
125 REVENUES & R&D EXPENDITURE
126 TOTAL REVENUES & R&D EXPENDITURE
127 REVENUES, BY BUSINESS SEGMENTS
128 REVENUES, BY PRODUCTS
129 REVENUES, BY GEOGRAPHY ($MILLION)
130 TOTAL REVENUES & EXPENDITURE
131 TOTAL REVENUES & R&D EXPENDITURE
132 NEKTAR – TOTAL REVENUES & R&D EXPENSES
133 NEKTAR – TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
134 QLT – TOTAL REVENUES & R&D EXPENSES ($MILLION)
135 QLT – TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
136 TOTAL REVENUES & R&D EXPENSES ($MILLION)
137 SURMODICS INC. – TOTAL REVENUES & R&D EXPENSES ($MILLION)
138 SURMODICS INC. – TOTAL REVENUES, BY GEOGRAPHY ($MILLION)
139 SURMODICS INC. – TOTAL REVENUES, BY SEGMENTS ($MILLION)
140 TOTAL REVENUES & R&D EXPENDITURE
141 YPSOMED - TOTAL REVENUES & R&D EXPENSES ($MILLION)
142 YPSOMED - TOTAL REVENUES, BY SEGMENTS ($MILLION)
LIST OF FIGURES
1 REVENUE ANALYSIS OF THE TOP 10 DRUG DELIVERY TECHNOLOGIES
2 TOP 10 DRUG DELIVERY TECHNOLOGIES – MARKET SHARE
3 EVOLUTION OF DRUG DELIVERY TECHNOLOGY INDUSTRY
4 ROLE OF DRUG DELIVERY TECHNOLOGIES IN A DRUG LIFE CYCLE
5 DRUG DELIVERY TECHNOLOGIES AS REVENUE DRIVERS
6 DRUG DELIVERY MARKET STAKEHOLDERS
7 IMPACT OF MARKET DRIVERS & RESTRAINTS
8 COMPARATIVE ANALYSIS OF DRUG DELIVERY TECHNOLOGIES
9 PATENT ANALYSIS, BY SEGMENTS (2004 – 2009)
10 PATENT ANALYSIS, BY ASSIGNEE (2004 – 2009)
11 COMMON REASONS FOR FAILURE OF DRUGS IN DRUG DISCOVERY/ DEVELOPMENT PROCESS
12 EVOLUTION OF CONTROLLED RELEASE TECHNOLOGIES
13 CONTROLLED RELEASE VS IMMEDIATE RELEASE
14 TARGETED THERAPY TYPES
15 EVOLUTION OF ENCAPSULATION TECHNOLOGIES
16 ENCAPSULATION APPLICATIONS IN DIFFERENT MODES OF DRUG DELIVERY
17 EVOLUTION OF INHALER TECHNOLOGY
18 FACTORS AFFECTING SELECTION OF INJECTABLE DEVICE
19 COMPETITIVE DEVELOPMENTS (2007 – JUNE 2010)
20 COMPETITIVE DEVELOPMENTS, BY SEGMENTS (2007 – JUNE 2010)
21 REVENUE ANALYSIS (2008 – 2009)
22 CONTROLLED RELEASE, DRUG FORMULATION – MARKET SHARE
23 R&D EXPENDITURE (2008 – 2009)
24 INJECTABLE DRUG DELIVERY DEVICES, MARKET SHARE
25 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET
26 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET – NORTH AMERICA
27 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET – EUROPE
28 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET – ASIA
29 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET – ROW
1 REVENUE ANALYSIS OF THE TOP 10 DRUG DELIVERY TECHNOLOGIES
2 TOP 10 DRUG DELIVERY TECHNOLOGIES – MARKET SHARE
3 EVOLUTION OF DRUG DELIVERY TECHNOLOGY INDUSTRY
4 ROLE OF DRUG DELIVERY TECHNOLOGIES IN A DRUG LIFE CYCLE
5 DRUG DELIVERY TECHNOLOGIES AS REVENUE DRIVERS
6 DRUG DELIVERY MARKET STAKEHOLDERS
7 IMPACT OF MARKET DRIVERS & RESTRAINTS
8 COMPARATIVE ANALYSIS OF DRUG DELIVERY TECHNOLOGIES
9 PATENT ANALYSIS, BY SEGMENTS (2004 – 2009)
10 PATENT ANALYSIS, BY ASSIGNEE (2004 – 2009)
11 COMMON REASONS FOR FAILURE OF DRUGS IN DRUG DISCOVERY/ DEVELOPMENT PROCESS
12 EVOLUTION OF CONTROLLED RELEASE TECHNOLOGIES
13 CONTROLLED RELEASE VS IMMEDIATE RELEASE
14 TARGETED THERAPY TYPES
15 EVOLUTION OF ENCAPSULATION TECHNOLOGIES
16 ENCAPSULATION APPLICATIONS IN DIFFERENT MODES OF DRUG DELIVERY
17 EVOLUTION OF INHALER TECHNOLOGY
18 FACTORS AFFECTING SELECTION OF INJECTABLE DEVICE
19 COMPETITIVE DEVELOPMENTS (2007 – JUNE 2010)
20 COMPETITIVE DEVELOPMENTS, BY SEGMENTS (2007 – JUNE 2010)
21 REVENUE ANALYSIS (2008 – 2009)
22 CONTROLLED RELEASE, DRUG FORMULATION – MARKET SHARE
23 R&D EXPENDITURE (2008 – 2009)
24 INJECTABLE DRUG DELIVERY DEVICES, MARKET SHARE
25 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET
26 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET – NORTH AMERICA
27 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET – EUROPE
28 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET – ASIA
29 TOP 10 DRUG DELIVERY TECHNOLOGIES MARKET – ROW
